UK Rare Biomarkers Specimen Collection And Stabilization Market Size & Outlook

The rare biomarkers specimen collection and stabilization market in UK is expected to reach a projected revenue of US$ 4,111.8 million by 2030. A compound annual growth rate of 14.1% is expected of UK rare biomarkers specimen collection and stabilization market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,890.6
Forecast, 2030 (US$M)
$4,111.8
CAGR, 2025 - 2030
14.1%
Report Coverage
UK

UK rare biomarkers specimen collection and stabilization market, 2018-2030 (US$M)

UK
Unlock Premium

Related Markets

UK rare biomarkers specimen collection and stabilization market highlights

  • The UK rare biomarkers specimen collection and stabilization market generated a revenue of USD 1,890.6 million in 2024 and is expected to reach USD 4,111.8 million by 2030.
  • The UK market is expected to grow at a CAGR of 14.1% from 2025 to 2030.
  • In terms of segment, circulating cell free dna (ccfdna) was the largest revenue generating biomarker in 2024.
  • Circulating Cell Free RNA (ccfRNA) / miRNA is the most lucrative biomarker segment registering the fastest growth during the forecast period.

Rare biomarkers specimen collection and stabilization market data book summary

Market revenue in 2024USD 1,890.6 million
Market revenue in 2030USD 4,111.8 million
Growth rate14.1% (CAGR from 2025 to 2030)
Largest segmentCirculating cell free dna (ccfdna)
Fastest growing segmentCirculating Cell Free RNA (ccfRNA) / miRNA
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCirculating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA
Key market players worldwideQiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR

Other key industry trends

  • In terms of revenue, UK accounted for 4.5% of the global rare biomarkers specimen collection and stabilization market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany rare biomarkers specimen collection and stabilization market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 4,111.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Biomarkers Specimen Collection And Stabilization Market Companies

Name Profile # Employees HQ Website

UK rare biomarkers specimen collection and stabilization market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.


Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 39.97% in 2024. Horizon Databook has segmented the UK rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.


Collaborations between homegrown companies with international companies to capitalize commercial opportunities in this market are anticipated to boost revenue growth in this market. For instance, in April 2019, ANGLE plc announced the use of its Parsortix system, a system that captures cells for isolation of CTCs and ctDNA.

The University of Texas MD Anderson Cancer Center for development of new technique to assess the metastatic potential of breast cancer. Furthermore, transportation of blood collection tubes with blood samples in compliance with IATA DGR (air transport) or ADR (transport by road) packing instructions 650 between clinic and laboratory is expected to positively impact the market in the coming years.

Reasons to subscribe to UK rare biomarkers specimen collection and stabilization market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK rare biomarkers specimen collection and stabilization market databook

  • Our clientele includes a mix of rare biomarkers specimen collection and stabilization market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This country databook contains high-level insights into UK rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK rare biomarkers specimen collection and stabilization market size, by biomarker, 2018-2030 (US$M)

UK Rare Biomarkers Specimen Collection And Stabilization Market Outlook Share, 2024 & 2030 (US$M)

UK rare biomarkers specimen collection and stabilization market size, by biomarker, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more